Compass Therapeutics Inc (NASDAQ:CMPX) Reports Wider Q2 2025 Loss, Shares Show Mixed Reaction Amid Clinical Progress

Compass Therapeutics Inc (NASDAQ:CMPX) Reports Q2 2025 Results: Wider Loss Than Expected, Market Shows Mixed Reaction

Compass Therapeutics Inc, a clinical-stage biopharmaceutical company focused on developing antibody-based oncology treatments, reported its second-quarter 2025 financial results. The company posted an earnings per share (EPS) of -$0.14, missing analyst estimates of -$0.1265. Revenue for the quarter came in at $0.0, in line with expectations.

Key Financial Takeaways

• EPS Miss: The reported loss of $0.14 per share was wider than the anticipated $0.1265 loss, reflecting higher operational costs or R&D expenses.
• Revenue In Line: As expected, the company generated no revenue, consistent with its clinical-stage status.
• Market Reaction: In pre-market trading, shares rose ~1.85%, suggesting some investor optimism despite the earnings miss. However, the stock has declined ~8.5% over the past week and ~15.1% over the last two weeks, indicating broader uncertainty.

Business and Clinical Updates

The company provided updates on its clinical pipeline, including progress in its Phase 2/3 study of tovecimig (CTX-009), a bispecific antibody targeting DLL4 and VEGF-A for advanced biliary tract cancer. Early data suggests fewer deaths in the treatment group, a potentially encouraging signal for efficacy.

Compass also continues development of:

• CTX-471, an agonist antibody targeting CD-137 (TNFRSF9) to stimulate immune response.
• CTX-8371, a bispecific antibody against PD-1 and PD-L1, key immune checkpoint inhibitors.

Outlook vs. Analyst Estimates

Analysts expect continued losses, projecting:

• Q3 2025 EPS: -$0.1335 (vs. -$0.14 in Q2).
• Full-Year 2025 EPS: -$0.5114, with no revenue anticipated.

The lack of forward guidance from Compass leaves investors reliant on clinical progress rather than near-term financial performance.

Market Sentiment

The pre-market uptick suggests some investors are focusing on long-term pipeline potential rather than the immediate earnings miss. However, the recent two-week decline indicates lingering concerns over cash burn and the timeline to commercialization.

For a deeper dive into Compass Therapeutics' earnings and estimates, visit the earnings and estimates page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research before making any financial decisions.